ATRC · AtriCure

The thesis

AtriCure's shares are modestly more likely than not to beat the S&P 500 over the next three months, because the 3 November 2026 third-quarter report gave the profit-led re-rating real revenue support. Revenue of $154.5 million rose 15.0% year over year, and the company raised fiscal 2026 adjusted earnings per share (EPS) guidance to $0.40–$0.46. The fourth-quarter report in early 2027, and whether pain-management growth holds, decide it.

The post-report gain has faded. The shares closed at $65.53 on 4 November 2026 and at $57.53 on 11 November 2026, 12.9% below the 52-week intraday high of $66.02 set on 4 November 2026. That close sits below every post-report analyst target: Needham, Piper Sandler and BTIG each set $70 on 4 November 2026, and Canaccord Genuity set $67.

The price already reflects the raised 2026 guidance: the shares rose 32.3% over three months to 11 November 2026, while the market has not paid up to the $67–$70 post-report targets. The rating is Medium because the raised guidance and the faster pain-management growth are filed facts. Against that, insiders sold through November and the shares gave back part of the move within a week of the report.

The weak part of the business is hybrid ablation, a minimally invasive surgical procedure that is losing patients to pulsed-field ablation catheters. That segment fell about 22% in the third quarter. It is the main drag the faster-growing segments have to outrun.

Bullish and bearish views on AtriCure, Inc.

The bull case on AtriCure, Inc. (ATRC), in brief: revenue growth now backs the profit story. The bear case: hybrid ablation keeps shrinking.

Bull case

• Revenue growth now backs the profit story. Third-quarter revenue was $154.5 million, up 15.0% (15.1% in constant currency), and US revenue was $128.0 million, up 17.1% (Form 8-K Exhibit 99.1, 3 November 2026). The 10-Q filed 4 November 2026 shows $154.45 million against $134.27 million a year earlier.
• Profit guidance moved sharply higher. Adjusted EPS guidance rose from $0.24–$0.32 to $0.40–$0.46, and GAAP EPS guidance from $0.05–$0.13 to $0.21–$0.27 (Form 8-K, 3 November 2026). Adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) guidance is $91–$94 million, and the revenue range moved to $606–$610 million from $602–$610 million.
• Pain management is accelerating. The segment reached $30.5 million in the third quarter, up about 33% year over year, against 27.8% growth reported for the second quarter on 23 July 2026. Management credited adoption of its newer cryoablation probe on the 3 November 2026 earnings call.
• Margins widened. Gross margin was 77.3%, up 180 basis points year over year, and adjusted EBITDA was $26.8 million, up 51% (Form 8-K, 3 November 2026). Cash stood at $187.0 million on 30 September 2026.
• Post-report targets sit above the price. Needham, Piper Sandler and BTIG raised their targets to $70 on 4 November 2026, and Canaccord Genuity kept its Buy rating while raising its target to $67. The 11 November 2026 close of $57.53 is below all four.

Bear case

• Hybrid ablation keeps shrinking. Minimally invasive ablation revenue was $7.3 million in the third quarter, down about 22% year over year, as physicians shift to pulsed-field catheters (Form 8-K, 3 November 2026).
• International growth is slow. International revenue of $26.4 million rose 5.8% (6.1% in constant currency), against 17.1% in the United States (Form 8-K, 3 November 2026). Management had flagged international execution problems on 8 September 2026.
• Profit fell from the prior quarter. Third-quarter net income was $4.1 million, or $0.08 per share, against $9.0 million in the second quarter. Adjusted EBITDA of $26.8 million was below the $27.3 million reported on 23 July 2026.
• Insiders kept selling into the rise. Chief Technical Officer Salvatore Privitera sold 8,404 shares at $65.00 on 4 November 2026 under a Rule 10b5-1 plan, and director Kristine Johnson sold 2,452 shares at $58.48 on 6 November 2026 (SEC Form 4 filings of 5 November 2026 and 10 November 2026). Director Regina Groves sold 5,313 shares at $54.22 on 11 September 2026, and Chief Legal Officer Karl Dahlquist sold 9,370 shares at $48.89 on 24 August 2026.
• The post-report gain has faded. The shares closed at $65.53 on 4 November 2026, $61.28 on 5 November 2026 and $56.26 on 10 November 2026, even though guidance was raised. The earnings multiple stays high because profits are only now emerging.

Price setup

The last close was $57.53 on 11 November 2026. The 52-week intraday high is $66.02, set on 4 November 2026, the first session after the report, and the 52-week closing low is $25.86 on 2 June 2026. The 3-month change is 32.3%, measured from the $43.49 close on 13 August 2026.

The 50-day moving average was $57.32 on 11 November 2026, so the shares closed just above it after dipping below it at $56.26 on 10 November 2026. The 200-day moving average was $38.9 on the same date, well beneath the price.

Two insider-sale prices bracket the recent trading. The director sale at $58.48 on 6 November 2026 sits just above the last close. The September director sale at $54.22 sits below every close since the report. No company-announced report date falls in the 30 days after 12 November 2026. The next scheduled test is the fourth-quarter report, which the company has not yet dated.

Catalysts ahead

• ~31 December 2026 (est.): Targeted completion of BoxX-NoAF trial enrolment, per Needham's 2 September 2026 note. The clinical half of the case assumes enrolment finishes on time, with first results in the first half of 2027.
• ~Feb 2027 (est.): Fourth-quarter and full-year 2026 report, with first fiscal 2027 guidance. It shows whether full-year revenue lands inside the $606-$610 million guide, whether pain-management growth holds near the Q3 rate, and what 2027 growth the company guides to.

What would change the view

A daily close below $54, under the $54.22 price of the 11 September 2026 director sale and below every close since the report, which would show the re-rating failing. Fourth-quarter revenue that leaves fiscal 2026 below the $606 million low end of guidance would also break the case.

The risks this note tracks, each with what would confirm it:

• Hybrid ablation keeps shrinking as physicians adopt pulsed-field catheters, and international sales stay weak. Confirmed by: minimally invasive ablation revenue falling further below the $7.3 million reported for Q3 2026, or international growth staying near 6%.
• Pain-management growth slows, removing the segment that has been offsetting weaker lines. Confirmed by: Q4 2026 pain-management growth falling well below the roughly 33% rate in Q3 2026.
• Competition from Medtronic and Edwards erodes the appendage-management franchise. Confirmed by: appendage-management revenue declining year over year, or management describing account losses to competing devices.
• The BoxX-NoAF clinical timetable slips. Confirmed by: AtriCure saying enrolment will not finish by the end of 2026.
• Fiscal 2027 guidance resets expectations lower than the Q3 2026 growth rate implies. Confirmed by: 2027 revenue guidance at the fourth-quarter report implying growth well below the 15.0% reported for Q3 2026.

What it trades with

AtriCure trades with US small-cap medical-device shares, and since 21 September 2026 with S&P SmallCap 600 index flows. Its appendage-management franchise competes with Medtronic's Penditure and Edwards' ECLIPTIS. Its hybrid-ablation line moves inversely with adoption of pulsed-field ablation catheters from larger electrophysiology device makers. Hospital cardiac-surgery scheduling drives quarterly volumes.